Literature DB >> 15951294

Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.

Kewal Asosingh1, Hendrik De Raeve, Mark de Ridder, Guy A Storme, Angelo Willems, Ivan Van Riet, Benjamin Van Camp, Karin Vanderkerken.   

Abstract

BACKGROUND AND OBJECTIVES: Unlike most other tumors, multiple myeloma (MM) cells have to survive and to grow in a bone marrow (BM) microenvironment which is already hypoxic by nature. BM hypoxia is crucial for normal hematopoiesis. However, how BM hypoxia and MM affect each other is unknown. We addressed this topic in the 5T2MM mouse model. DESIGN AND METHODS: Levels of hypoxia in the BM of control and tumor-bearing mice were analyzed by flow cytometric analysis of pimonidazole hypoxyprobe binding and hypoxia-inducible factor 1alpha (HIF-1alpha) expression. Micro-vessel density was measured by CD31 staining of BM sections for immunohistochemistry. Apoptosis sensitivity of CD45 5T2MM subsets in hypoxic conditions were analyzed by detection of active caspase-3.
RESULTS: Analysis of control and 5T2MM diseased mice injected with pimonidazole hypoxyprobe indicated that both normal BM and myeloma-infiltrated BM are hypoxic. However, the hypoxia in the myelomatous BM was significantly decreased. Analysis of HIF-1alpha expression, a surrogate marker of hypoxia, also demonstrated significantly lower levels of hypoxia in myeloma-infiltrated BM. HIF-1alpha expression was inversely correlated with the micro-vessel density. In vitro culture of 5T2MM cells under hypoxic conditions indicated induction of apoptosis in the CD45- MM-fraction, but not in the CD45+ 5T2MM-cells. INTERPRETATION AND
CONCLUSIONS: These data suggest that native BM hypoxia is advantageous for the tumor-initiating CD45+ 5T2MM-cells. Together with the decreased hypoxia in myeloma-infiltrated BM it also indicates that myeloma-associated angiogenesis is functional and permissive for the expansion of CD45- 5T2MM-cells. All together the data raise the possibility of an important role of BM hypoxia in myeloma tumor progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951294

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  42 in total

1.  Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy.

Authors:  Toru Imai; Barbara Muz; Cheng-Hung Yeh; Junjie Yao; Ruiying Zhang; Abdel Kareem Azab; Lihong Wang
Journal:  Cancer Biol Ther       Date:  2017-01-03       Impact factor: 4.742

2.  Hypoxia inducible factor-1 alpha and multiple myeloma.

Authors:  Archana Bhaskar; Bhupendra Nath Tiwary
Journal:  Int J Adv Res (Indore)       Date:  2016-01-01

3.  Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma.

Authors:  Charvann K Bailey; Anna Budina-Kolomets; Maureen E Murphy; Yulia Nefedova
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

4.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

5.  Mimicking the functional hematopoietic stem cell niche in vitro: recapitulation of marrow physiology by hydrogel-based three-dimensional cultures of mesenchymal stromal cells.

Authors:  Monika B Sharma; Lalita S Limaye; Vaijayanti P Kale
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 6.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

Review 7.  Image-guided nanosystems for targeted delivery in cancer therapy.

Authors:  A K Iyer; J He; M M Amiji
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

8.  Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.

Authors:  Pilar de la Puente; Feda Azab; Barbara Muz; Micah Luderer; Jack Arbiser; Abdel Kareem Azab
Journal:  Leuk Lymphoma       Date:  2015-11-16

9.  Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

Authors:  Sally K Martin; Peter Diamond; Sharon A Williams; Luen Bik To; Daniel J Peet; Nobutaka Fujii; Stan Gronthos; Adrian L Harris; Andrew C W Zannettino
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

10.  Differentiation stage-specific requirement in hypoxia-inducible factor-1alpha-regulated glycolytic pathway during murine B cell development in bone marrow.

Authors:  Hidefumi Kojima; Ayano Kobayashi; Daisuke Sakurai; Yumiko Kanno; Hidenori Hase; Riichi Takahashi; Yoshikazu Totsuka; Gregg L Semenza; Michail V Sitkovsky; Tetsuji Kobata
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.